Press

Together We’re Fueling the Midwest Tech Boom

Rev1 in the News

How to Use Milestone Mapping to Chart a Path for Startup Growth
Rev1 News
How to Use Milestone Mapping to Chart a Path for Startup Growth
Kristy Campbell is driven to help startups
Rev1 News
Kristy Campbell is driven to help startups
50 Columbus-Based Startups on Display at Annual Innovation Hop
Rev1 News
50 Columbus-Based Startups on Display at Annual Innovation Hop
Rev1’s Innovation Hop: Bold startups. Big ideas. One night only.
Rev1 News
Rev1’s Innovation Hop: Bold startups. Big ideas. One night only.
71/70 Angels launches first fund to expand Ohio’s angel investor network
Rev1 News
71/70 Angels launches first fund to expand Ohio’s angel investor network
Load More

Buzz About Our Companies

Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer
Company News, Funding News
Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer
71/70 Angels, Interview With Managing Director Melinda Gloriosa
Company News
71/70 Angels, Interview With Managing Director Melinda Gloriosa
Neucore Bio Awarded Competitive Grant from the U.S. National Science Foundation for Research on Scalability of Exosome-based Therapeutics for Genetic Disease
Company News, Funding News
Neucore Bio Awarded Competitive Grant from the U.S. National Science Foundation for Research on Scalability of Exosome-based Therapeutics for Genetic Disease
Neucore Bio Awarded Competitive Grant from the U.S. National Science Foundation for Research on Scalability of Exosome-based Therapeutics for Genetic Disease
Company News
Neucore Bio Awarded Competitive Grant from the U.S. National Science Foundation for Research on Scalability of Exosome-based Therapeutics for Genetic Disease
Clarametyx Biosciences Announces FDA Grant Of Fast Track And Qualified Infectious Disease Product Designations For CMTX-101
Company News
Clarametyx Biosciences Announces FDA Grant Of Fast Track And Qualified Infectious Disease Product Designations For CMTX-101
Load More

Accolades

Pitchbook
Pitchbook: #1 Most Active VC in Ohio

2014 – 2018

cbinsights
CB Insights: #1 Most Active VC in Ohio

2014 – 2018

Pitchbook
Pitchbook: #2 Most Active VC in the Great Lakes

2017 – 2018

Pitchbook
Pitchbook: #9 Most Active Angel & Seed Investor in United States

2018

SSTI
SSTi: Excellence in Technology Based Economic Development Award

2012 – Increasing Access to Capital

Pitchbook
Pitchbook: #1 Most Active VC in Ohio

2014 – 2018

cbinsights
CB Insights: #1 Most Active VC in Ohio

2014 – 2018

Pitchbook
Pitchbook: #2 Most Active VC in the Great Lakes

2017 – 2018

Pitchbook
Pitchbook: #9 Most Active Angel & Seed Investor in United States

2018

SSTI
SSTi: Excellence in Technology Based Economic Development Award

2012 – Increasing Access to Capital

Press Inquiries?

For media inquiries or introductions to any of our portfolio clients, contact Ashley Baig, Director of Marketing and Communications.

Email Ashley